Search results for "time factor"

showing 10 items of 3219 documents

Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly admin…

2008

Abstract The primary purpose of this paper is to present the available evidence for the administration of cetuximab on an every-2-weeks basis in combination with irinotecan in metastatic colorectal cancer (mCRC). Cetuximab is an epidermal growth factor receptor–targeted IgG1 monoclonal antibody that is approved for use in combination with irinotecan or as monotherapy in the treatment of mCRC. The currently approved dosing regimen for cetuximab is a 400-mg/m2 initial dose followed by 250 mg/m2 weekly. Many commonly used chemotherapy agents for mCRC (including irinotecan alone or in combination with 5-fluorouracil [5-FU]/folinic acid [FA] and oxaliplatin plus 5-FU/FA) are administered on an e…

OncologyCancer Researchmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentCetuximabAntineoplastic AgentsPharmacologyAntibodies Monoclonal HumanizedIrinotecanFolinic acidPharmacokineticsInternal medicinemedicineHumansDosingneoplasmsChemotherapyCetuximabbusiness.industryAntibodies Monoclonaldigestive system diseasesOxaliplatinIrinotecanRegimenOncologyCamptothecinbusinessColorectal Neoplasmsmedicine.drugThe oncologist
researchProduct

Nm-23-H1 expression does not predict clinical survival in colorectal cancer patients

2003

The gene Nm23, which encodes for a nucleoside diphosphate kinase, has been defined as a metastasis-suppressor gene because of the inverse correlation between its expression and the metastatic capacity of the tumor cells. For colorectal cancer, however, the findings are equivocal. The aim of our study was to assess, in 160 patients undergoing surgery for colorectal cancer (CRC), the expression of the Nm23-H1 protein and to evaluate its possible associations with traditional clinicopathologic variables, with DNA-ploidy and proliferative activity (S-phase fraction, SPF), and with disease-free and overall survival of patients. Nm23-H1 expressions were evaluated on paraffin-embedded tissue by im…

OncologyCytoplasmCancer Researchmedicine.medical_specialtyPathologyTime FactorsSettore MED/06 - Oncologia MedicaColorectal cancerBiologyDisease-Free SurvivalS PhaseInternal medicineNm23-H1 expressionmedicineHumansClinical significancePloidiesModels GeneticOncogeneCancerExonsGeneral MedicineNM23 Nucleoside Diphosphate KinasesCell cycleFlow CytometryPrognosismedicine.diseaseImmunohistochemistryColorectal cancerMolecular medicineOncologyTumor progressionNucleoside-Diphosphate KinaseProtein BiosynthesisDisease ProgressionImmunohistochemistryColorectal NeoplasmsCell Division
researchProduct

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

2017

Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or observation in several randomized controlled trials (RCTs) of patients with newly diagnosed multiple myeloma (NDMM). All studies had PFS as the primary end point, and none were powered for overall survival (OS) as a primary end point. Thus, a meta-analysis was conducted to better understand the impact of lenalidomide maintenance in this setting. Patients and Methods The meta-analysis was conducted using primary-source patient-level data and documentation from three RCTs (Cancer and Leukemia Group B 100104, Gruppo Italiano Malatti…

OncologyMaleCancer ResearchTime FactorsAngiogenesis InhibitorsKaplan-Meier Estimatelaw.invention0302 clinical medicineAutologous stem-cell transplantationMaintenance therapyRandomized controlled triallawRisk FactorsClinical endpointMedicine10. No inequalityLenalidomideAdjuvantMultiple myelomaRandomized Controlled Trials as TopicHematopoietic Stem Cell TransplantationMESH: Angiogenesis Inhibitors/administration & dosageORIGINAL REPORTSMiddle Aged3. Good healthThalidomideAdult; Aged; Angiogenesis Inhibitors; Chemotherapy Adjuvant; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Randomized Controlled Trials as Topic; Risk Factors; Thalidomide; Time Factors; Transplantation Autologous; Treatment Outcome; Young Adult; Stem Cell TransplantationTreatment OutcomeOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisDisease ProgressionMESH: Multiple Myeloma/therapyFemaleMultiple MyelomaAutologousmedicine.drugAdultmedicine.medical_specialtyMESH: Thalidomide/analogs & derivatives[SDV.CAN]Life Sciences [q-bio]/CancerTransplantation AutologousDisease-Free SurvivalDrug Administration ScheduleMaintenance Chemotherapy03 medical and health sciencesYoung AdultInternal medicineChemotherapyHumansLenalidomideAgedTransplantationbusiness.industrymedicine.diseaseThalidomideTransplantationbusiness030215 immunologyStem Cell Transplantation
researchProduct

c-erbB-2 expression in small-cell lung cancer is associated with poor prognosis.

2001

Small-cell lung cancer (SCLC) carries a bad prognosis despite good initial response to chemotherapy. It is therefore important to identify molecular markers that influence survival as potential new therapeutic targets. In our study, expression of the tyrosine kinase c-erbB-2 (HER2/neu) receptor in tumor tissues of 107 consecutive newly diagnosed patients with primary SCLC was quantified using a monoclonal antibody directed against the c-terminal domain of c-erbB-2. A clear-cut positive expression of c-erbB-2 was observed in 13% of patients. Surprisingly, c-erbB-2 was an independent prognostic factor (RR = 2.16; p = 0.014) when a proportional-hazard model was adjusted to stage (limited vs. e…

OncologyMaleCancer Researchmedicine.medical_specialtyPathologyLung NeoplasmsTime FactorsReceptor ErbB-2medicine.medical_treatmentSmall-cell carcinomaDisease-Free SurvivalSex FactorsInternal medicinemedicineCarcinomaHumansCarcinoma Small CellLung cancerneoplasmsAgedProportional Hazards ModelsChemotherapyPerformance statusL-Lactate DehydrogenaseProportional hazards modelbusiness.industryAge FactorsCancerAntibodies MonoclonalMiddle Agedmedicine.diseasePrognosisImmunohistochemistryProtein Structure TertiaryTreatment OutcomeOncologyPhosphopyruvate HydrataseImmunohistochemistryFemalebusinessInternational journal of cancer
researchProduct

(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase…

2012

Purpose We report on a multicenter phase II trial of 90yttrium-ibritumomab-tiuxetan (90YIT) as first-line stand-alone therapy for patients with follicular lymphoma (FL). Patients and Methods Fifty-nine patients with CD20+ FL grade 1 to 3a in stages II, III, or IV, age 50 years old or older requiring therapy were enrolled. They received 90YIT according to standard procedure. If complete response (CR) or unconfirmed complete response (CRu) without evidence for minimal residual disease (MRD) 6 months after application of 90YIT was achieved, patients were observed without further intervention. The same applied to patients with partial response (PR) or with stable disease (SD). Patients with CR …

OncologyMaleCancer Researchmedicine.medical_specialtyPathologyNeoplasm ResidualTime FactorsFollicular lymphomaIbritumomab tiuxetanAntineoplastic AgentsDisease-Free SurvivalInternal medicinemedicineHumansLymphoma FollicularAgedNeoplasm StagingProportional Hazards ModelsAged 80 and overbusiness.industryFollow up studiesAntibodies MonoclonalMiddle AgedRadioimmunotherapymedicine.diseaseLymphomaFirst line treatmentClinical trialOncologyMulticenter studyNeoplasm stagingFemalebusinessmedicine.drugFollow-Up StudiesJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Time trends of cancer incidence in European children (1978-1997): Report from the Automated Childhood Cancer Information System project.

2006

Within the framework of the Automated Childhood Cancer Information System (ACCIS), time trend analyses for childhood cancer were performed using data from 33 population-based cancer registries in 15 European countries for the period 1978-1997. The overall incidence rate based on 77,111 cases has increased significantly (P<0.0001), with an average annual percentage change (AAPC) of 1.1%. The rising trend was observed in all five geographical regions and in the majority of the disease groups (in order of AAPC): soft tissue sarcomas (1.8%), brain tumours, tumours of the sympathetic nervous system, germ-cell tumours, carcinomas, lymphomas, renal tumours, and leukaemias (0.6%). No change was see…

OncologyMaleCancer Researchmedicine.medical_specialtyPediatricsTime FactorsAdolescentDatabases FactualPopulationChildhood cancerDiseaseInternal medicineNeoplasmsEpidemiologymedicineHumansRegistrieseducationChildeducation.field_of_studyTime trends - cancer incidence - European childrenbusiness.industryRetinoblastomaIncidence (epidemiology)IncidenceInfant NewbornCancerInfantmedicine.diseaseEuropeOncologyEl NiñoChild PreschoolFemalesense organsbusiness
researchProduct

P-cadherin expression and survival rate in oral squamous cell carcinoma: an immunohistochemical study

2005

Abstract Background P-cadherin (P-cad) is a transmembrane molecule involved in the cell-cell adhesion and similar to E-cadherin (E-cad), but less investigated in oncology, especially in in vivo studies. Aims of the present study were to assess the prevalence of P-cad expression in oral squamous cell carcinoma (OSCC) and to verify whether P-cad can be considered a marker of prognosis in patients with OSCC. Methods In a retrospective study, a cohort of 67 OSCC patients was investigated for P-cad expression and its cellular localization by immunohistochemistry; some respective healthy margins of resection were similarly investigated as standard controls. After grouping for P-cad expression, OS…

OncologyMalePathologyCancer ResearchCytoplasmTime FactorsCohort StudiesSurgical oncologyCellular localizationMouth neoplasmAged 80 and overMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCadherinsPrognosisImmunohistochemistryTreatment OutcomeOncologycell-cell adhesionCarcinoma Squamous CellImmunohistochemistryRegression AnalysisFemaleMouth NeoplasmsResearch ArticleAdultmedicine.medical_specialtyAdolescentlcsh:RC254-282Internal medicinemedicineGeneticsBiomarkers TumorHumanscardiovascular diseasesGrading (tumors)Survival rateAgedProportional Hazards ModelsRetrospective StudiesModels StatisticalProportional hazards modelCadherinbusiness.industryCell MembraneCateninstomatognathic diseasesMultivariate AnalysisCadherinbusinessCell Adhesion Molecules
researchProduct

Detection and characterization of tumor hypoxia using pO2 histography.

2007

Data from 125 studies describing the pretreatment oxygenation status as measured in the clinical setting using the computerized Eppendorf pO2 histography system have been compiled in this article. Tumor oxygenation is heterogeneous and severely compromised as compared to normal tissue. Hypoxia results from inadequate perfusion and diffusion within tumors and from a reduced O2 transport capacity in anemic patients. The development of tumor hypoxia is independent of a series of relevant tumor characteristics (e.g., clinical size, stage, histology, and grade) and various patient demographics. Overall median pO2 in cancers of the uterine cervix, head and neck, and breast is 10 mm Hg with the ov…

OncologyMalePathologymedicine.medical_specialtyTime FactorsPhysiologyClinical BiochemistryUterine Cervical NeoplasmsBreast NeoplasmsBiochemistryInternal medicineNeoplasmsMedicineHumansOximetryStage (cooking)Neoplasm MetastasisHypoxiaMolecular BiologyGeneral Environmental ScienceTumor hypoxiabusiness.industryHistologyCell BiologyOxygenationHypoxia (medical)Tumor OxygenationPrognosisOxygenHead and Neck NeoplasmsGeneral Earth and Planetary SciencesFemaleHemoglobinmedicine.symptombusinessPerfusionSoftwareAntioxidantsredox signaling
researchProduct

Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma

2016

Background Prognostic assessment in patients with hepatocellular carcinoma (HCC) remains controversial. Using the Italian Liver Cancer (ITA.LI.CA) database as a training set, we sought to develop and validate a new prognostic system for patients with HCC. Methods and Findings Prospective collected databases from Italy (training cohort, n = 3,628; internal validation cohort, n = 1,555) and Taiwan (external validation cohort, n = 2,651) were used to develop the ITA.LI.CA prognostic system. We first defined ITA.LI.CA stages (0, A, B1, B2, B3, C) using only tumor characteristics (largest tumor diameter, number of nodules, intra- and extrahepatic macroscopic vascular invasion, extrahepatic metas…

OncologyMaleTime FactorsDatabases FactualCancer Treatmentlcsh:MedicinePredictive Value of TestPediatricsBiochemistryGeographical locationsNeoplasms Multiple PrimaryDecision Support Technique0302 clinical medicineInterquartile rangeRetrospective StudieMultiple PrimaryRisk FactorsNeoplasmsMedicine and Health SciencesEthnicitiesPublic and Occupational HealthLiver DiseasesLiver NeoplasmsChild HealthGeneral MedicineMiddle AgedPrognosisItalian PeopleTumor BurdenQuartileOncologyCirrhosisItalyLiver Neoplasm030220 oncology & carcinogenesisPredictive value of testsCohortPerspectiveHong Kong030211 gastroenterology & hepatologyFemaleSurvival Analysialpha-FetoproteinsHumanBiotechnologymedicine.medical_specialtyCarcinoma HepatocellularAsiaTime FactorSettore MED/12 - GASTROENTEROLOGIAAged; Carcinoma Hepatocellular; Databases Factual; Decision Support Techniques; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms Multiple Primary; Predictive Value of Tests; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Taiwan; Time Factors; Tumor Burden; alpha-Fetoproteins; Biotechnology; Biochemistry; Molecular Biology; Cell BiologyTaiwanReproducibility of ResultGastroenterology and HepatologyCarcinomasRisk AssessmentDecision Support Techniques03 medical and health sciencesDatabasesDiagnostic MedicinePredictive Value of TestsInternal medicineGastrointestinal TumorsmedicineHumansNeoplasm Invasivenessalpha-FetoproteinMolecular BiologySurvival analysisFactualAgedNeoplasm StagingRetrospective StudiesNeoplasm InvasivenePerformance statusbusiness.industryRisk Factorlcsh:RCarcinomaCancers and NeoplasmsReproducibility of ResultsRetrospective cohort studyHepatocellularHepatocellular CarcinomaCell BiologySurvival AnalysisBCLC StageSurgeryPeople and PlacesPopulation Groupingsbusiness
researchProduct

Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fet…

2015

The lifetime utility of liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) is still controversial. The aim of this study was to ascertain when LT is cost-effective for HCC patients, with a view to proposing new transplant selection criteria. The study involved a real cohort of potentially transplantable Italian HCC patients (n = 2419 selected from the Italian Liver Cancer group database) who received nontransplant therapies. A non-LT survival analysis was conducted, the direct costs of therapies were calculated, and a Markov model was used to compute the cost utility of LT over non-LT therapies in Italian and US cost scenarios. Post-LT survival was calculated using t…

OncologyMaleTime FactorsDatabases Factualmedicine.medical_treatmentCost-Benefit AnalysisLiver transplantationClinical endpointLiver NeoplasmsSurgery; Transplantation; HepatologyHealth Care Costshepatocellular carcinomaMiddle AgedMarkov ChainsTumor BurdenModels EconomicTreatment OutcomeItalyHepatocellular carcinomaFemaleQuality-Adjusted Life Yearsalpha-FetoproteinsAlpha-fetoproteinMonte Carlo Methodmedicine.medical_specialtyCarcinoma HepatocellularSettore MED/12 - GASTROENTEROLOGIADecision Support Techniquesalpha-fetoproteinPredictive Value of TestsInternal medicinemedicineHumansneoplasmsSurvival analysisAgedProportional Hazards ModelsRetrospective StudiesTransplantationHepatologyProportional hazards modelbusiness.industryPatient SelectionRetrospective cohort studymedicine.diseaseSurvival Analysisdigestive system diseasesUnited StatesSurgeryLiver TransplantationTransplantationMultivariate AnalysisSurgerybusiness
researchProduct